Malignant Hyperthermia: Difference between revisions
No edit summary |
No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 22: | Line 22: | ||
[https://pubmed.ncbi.nlm.nih.gov/21169802/ Preparation of modern anesthesia workstations for malignant hyperthermia-susceptible patients: a review of past and present practice] | [https://pubmed.ncbi.nlm.nih.gov/21169802/ Preparation of modern anesthesia workstations for malignant hyperthermia-susceptible patients: a review of past and present practice] | ||
[https://pubs.asahq.org/anesthesiology/article/136/6/940/135870/Referral-Indications-for-Malignant-Hyperthermia Referral Indications for Malignant Hyperthermia Susceptibility Diagnostics in Patients without Adverse Anesthetic Events in the Era of Next-generation Sequencing] | [https://pubs.asahq.org/anesthesiology/article/136/6/940/135870/Referral-Indications-for-Malignant-Hyperthermia Referral Indications for Malignant Hyperthermia Susceptibility Diagnostics in Patients without Adverse Anesthetic Events in the Era of Next-generation Sequencing] | ||
| Line 34: | Line 32: | ||
[https://www.bjanaesthesia.org/article/S0007-0912(23)00189-7/fulltext What is malignant hyperthermia susceptibility?] | [https://www.bjanaesthesia.org/article/S0007-0912(23)00189-7/fulltext What is malignant hyperthermia susceptibility?] | ||
[https://pubmed.ncbi.nlm.nih.gov/37373564/ Real Evidence and Misconceptions about Malignant Hyperthermia in Children: A Narrative Review] | |||
[https://pubmed.ncbi.nlm.nih.gov/37787745/ Evaluation of Malignant Hyperthermia Features in Patients with Pathogenic or Likely Pathogenic RYR1 Variants Disclosed through a Population Genomic Screening Program] | |||
[https://pubmed.ncbi.nlm.nih.gov/38329334/ Improving Dantrolene Mobilization in Regions with Limited Availability] | |||
[https://pubs.asahq.org/monitor/article/88/7/1/141615/The-Story-Behind-the-MH-Hotline The Story Behind the MH Hotline] | |||
[https://www.bjanaesthesia.org/article/S0007-0912(24)00469-0/fulltext Propofol binds and inhibits skeletal muscle ryanodine receptor] | |||
Latest revision as of 13:36, 17 October 2024
This is a Stub Notice. This page has not been completed. You can work on this page by signing in and going to the Edit tab. Thanks for helping to make PedsAnesthesia.Net Wiki useful.
Go to the Main Page to see the Topic Outline.
Go to the Generalized Suggested Outline for information on case-specific details for each page.
Go to the Test Page for examples on how to use references in the page.
History of Malignant Hyperthermia
See also Malignant Hypertgermia Association of the United States
Malignant hyperthermia 2020 Guideline from the Association of Anaesthetists
Malignant Hyperthermia Resource Kit
Twitter Thread: Building an MH Cart
New device simplifies workstation preparation for malignant hyperthermia-susceptible patients
What is malignant hyperthermia susceptibility?
Real Evidence and Misconceptions about Malignant Hyperthermia in Children: A Narrative Review
Improving Dantrolene Mobilization in Regions with Limited Availability
The Story Behind the MH Hotline
Propofol binds and inhibits skeletal muscle ryanodine receptor